佛慈制药(002644) - 2015 Q3 - 季度财报

Financial Performance - Operating revenue decreased by 11.58% to CNY 94,632,885.79 compared to the same period last year[7] - Net profit attributable to shareholders increased by 17.19% to CNY 13,846,440.74 compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 19.16% to CNY 13,744,525.74 compared to the same period last year[7] - Basic earnings per share decreased by 12.86% to CNY 0.0271 compared to the same period last year[7] - Diluted earnings per share decreased by 12.86% to CNY 0.0271 compared to the same period last year[7] - The estimated net profit attributable to shareholders for 2015 is projected to range from ¥34.65 million to ¥45.05 million, indicating a potential growth of 0.00% to 30.00% compared to 2014[22] Assets and Liabilities - Total assets increased by 43.49% to CNY 1,501,828,776.85 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 66.43% to CNY 1,223,634,048.75 compared to the end of the previous year[7] - Cash and cash equivalents increased by 164.88% to ¥730.14 million, primarily due to the completion of a private placement[14] - Prepayments rose by 108.83% to ¥25.65 million, mainly due to land purchase prepayments by a subsidiary[15] - Short-term borrowings decreased by 42.31% to ¥15 million, reflecting repayment of bank loans[15] - Capital reserve increased by 61.77% to ¥328.01 million, mainly due to the premium from the private placement[15] Operating Activities - Cash flow from operating activities decreased by 51.98% to CNY 37,863,974.61 year-to-date[7] - Operating costs decreased by 25.26% to ¥191.54 million, attributed to a decline in medicinal material operating revenue[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,961[10] Financial Management - Financial expenses increased by 436.45% to -¥14.01 million, due to increased returns from idle raised funds[16] - The company has no securities investments during the reporting period[23] - The company did not hold shares in other listed companies during the reporting period[24] - The company is committed to not engaging in risk investments during the use of idle raised funds for working capital[21] Return on Equity - Weighted average return on equity increased to 1.14% from 0.50% at the end of the previous year[7]